This product is a structural analog of deoxyguanosine and can inhibit the replication of herpes viruses. Its mechanism of action involves ganciclovir being initially phosphorylated by a protein kinase homolog encoded by the UL97 gene of cytomegalovirus (CMV) to form a monophosphate salt. It is further phosphorylated into diphosphate and triphosphate forms by cellular kinases. In CMV-infected cells, the concentration of triphosphate is 100 times higher than that in uninfected cells, indicating that the product is preferentially phosphorylated in infected cells. Once ganciclovir is in the triphosphate form, it can persist in CMV-infected cells for several days. The triphosphate form of ganciclovir inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and incorporating into the DNA of both the virus and host cells, leading to termination of viral DNA elongation. Ganciclovir exhibits stronger inhibition on viral DNA polymerase compared to host polymerase.
Packaging：
Specifications： 50mg, 250mg
Shelf Life： 2 years
Approval Number： 国药准字H20055299 国药准字H20055300
Indications： This product is only used for: 1) Prevention of cytomegalovirus disease in organ transplant recipients at risk of developing CMV infection. 2) Treatment of cytomegalovirus retinitis in immunocompromised patients, including patients with AIDS.
Detail
1. Included in National Medical Insurance Category B, and covered by the New Rural Cooperative Medical Scheme.
2. Broad-spectrum and highly effective antiviral activity.
3. Relatively good safety and tolerability profile.
4. Can be used for antiviral treatment of hepatitis B.
5. A powerful weapon for treating viral diseases such as hand, foot, and mouth disease.
6. Pre-filled packaging for convenient use.
